Atrial Fibrillation Trial, Recruiting NCT07458191 Sponsor: Bosnalijek D.D Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT07458191
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People whose heart and circulation are stable (not in a state of shock or collapse)
  • People who have a type of irregular heartbeat called atrial fibrillation that is not caused by a problem with the heart valves
  • People whose doctor has decided, based on a clinical assessment, that starting apixaban (a blood-thinning medication) is appropriate for them
  • People who have never taken apixaban before

Who may not be able to join:

  • People with a history of a severe type of swelling called angioneurotic edema (a condition causing sudden swelling under the skin)
  • People who are currently experiencing significant active bleeding
  • People who have a bleeding disorder, whether inherited or developed over time
  • People who have a cancer diagnosis
  • People who currently have or have recently had a stomach or intestinal ulcer
  • People who have enlarged veins in the food pipe (esophageal varices), confirmed or suspected
  • People with a history of abnormal connections between arteries and veins, aneurysms, or unusual blood vessel formations in or around the spine or brain
  • People who have an artificial heart valve
  • People with liver cirrhosis or active liver disease that affects the blood's ability to clot, with a significant risk of bleeding
  • People whose kidneys are functioning at a very low level, including those on dialysis (confirm with trial site regarding specific kidney function thresholds)
  • People who are currently taking any other blood-thinning (anticoagulant) medications
  • People who are pregnant or breastfeeding
  • People who have used apixaban at any point in the past

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +387 62 478 535

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Bosnalijek D.D
Registry
ClinicalTrials.gov
Start date
9 October 2025
Est. completion
1 April 2027

Where this trial is recruiting

Bosnia and Herzegovina

Primary endpoints

Composite primary outcome including incidence of major bleeding and clinically relevant non-major bleeding

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov